Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The current price is based on actual historical performance. It is priced right for that. It doesn’t take much into consideration for future potential. Give it another couple of quarters and that will start to be priced in. As long as the price remains at these levels, driven by being on OTC and significant float, I’ll keep buying.
To clarify, the ANDAs are in markets, competitive markets, that are in the billions. Looking forward to next two biggies where there is greater penetration potential. Looking forward to see Prasco get cooking.
Including more vault space too
I think Purdue outcome (legal + FDA) and launch of next CNS drugs in pipeline are going to determine the timing. Would be nice to see 2nd gen R&D make some movement for increased value.
Launch volume for Prasco was included. Recurring orders were not as they didn’t exist as of 12/31. This was validated during call.
You can through overseas brokers, just not stateside. Requires considerable margin risk though.
Arm yourselves with tin cans and toss them at the goats. That should do the trick.
I know. Would be awesome. Overall market is smaller, but penetrable market is larger. Definitely bigger than Adderall. TBD on Vyvanse.
Nasrat set extremely high top line expectations last Q and fell short. Sales were great. It was a record quarter, but sales acceleration (as shown) has slowed. I think we’ll see a nice pickup in June, but until then, expectations have been tampered down. To say that we will exceed $40M when we have $38M is really silly. Companies on larger exchanges get hit due to similar tepid commentary. If market is forward looking and you don’t give updated guidance then you should expect stock price to fall flat. I think near term smaller ANDA approvals may provide a little lift. We’ll likely also hear about BE trial before next call as well for next CNS product.
Always thought the same thing. :D
Launch could only start Jan due to their prior contractual agreement. We supplied them with their requested launch volume in Dec so they could launch Jan 1. Now we should get revenue in Q4 for ongoing subsequent orders from Prasco.
You are welcome on Prasco revenue accounting. :)
I always enjoy this quarterly hold music…
I think this is a case of Nasrat hyped Q3 and failed to meet that hype. A little beat Q/Q, but nothing material, especially for what will eventually be a high growth situation. Looking forward to call.
TDA platform was light years better in data provided, uptime, speed, etc.
Schwab triggered issues right at opening bell with website, mobile app & login.
I actually disagree here. Pharma does have some seasonality to it, but for the most part these are ongoing prescriptions. Back to school and summer lull does impact Adderall specifically. We will see swings in initial fill quantities for new partners, launch with Prasco awaiting refill quantities, etc, but for most part the business should have stair step growth.
By time Q4 earnings call takes place in June, Elite will be fully integrated into new facility using that extra vault and storage space.
This is really amusing. Thanks for the humor. This is legendary. :D
Cash flow applies to all companies. My question was simply a general question to the board as it sounds many don’t understand the B/S and CF statements vs. P&L.
Elite doesn’t have cash flow issues as they have a ton they are simply sitting on waiting to collect in A/R. This B/S is historically looking back to a 12/31 snapshot so I’d think that they would have already collected on a huge amount of this already and reinvest that cash in inventory, to pay employees, utilities, PPE, etc.
Exactly and how quickly we collect that cash so we can reinvest it.
Question for the board. Can a company be extremely profitable and go bankrupt? Yes, because it’s all about the cash flow that keeps the lights on, people paid, inventory and vendors paid, etc. The faster we collect cash, the better. Often there are payment discounts if we are paid within terms (Net 30 2%, Net 60), meaning we’ll give you a 2% discount if you pay us in 30 days, otherwise pay the full amount within 60 days.
What?! Please explain why you would add A/R to sales? That’s double dipping.
A/R is for sales that have already taken place and recorded as revenue, but cash hasn’t collected yet. Are you saying growth in A/R Q/Q will just be invested in more inventory so cash flow cycle?
Little north of 14.1M for Q2
I’m guessing that mental health takes a toll when someone tries to generate offspring with goats.
He made 2 separate comments in the cc on Q3 rev, this being one:
“In the last three quarters from January till September, we've made more than $30 million. By the end of this quarter, this -- by December, we would be north of $40 million. Next year is going to be a bigger year, because we will have Presco in the mix.”
You must be Lowensteins alter ego. You edit comments as much as him. Wouldn’t be surprised in the slightest.
Why are you ignoring that question? How about basic accounting of contractual revenue recognition? How about speaking as if audience is a bunch of 5 year olds? Well, you are in the audience.
I knew I couldn’t mute a jackass that would try and take advantage of me putting them on mute.
How many times did Carter have to restate earnings? More than once. That is just one of the issues. Love how you celebrate mediocrity.
Absolutely correct. Revenue is recorded in period it is earned, which would be Dec launch.
They won’t get paid upon delivery. They will deliver product and A/P terms of 30-60 days are slapped on. Revenue is still recorded upon receipt of goods, cash flow comes later. So we should see on B/S a receivable for the Prasco initial volume and any follow up volume needs since launch.
Absolutely. Mid-way through Q4, I’m hoping we get some visibility to how Q4 is expected to fare vs Q3. The confidence that Nasrat had last call may have surpassed the “FDA cannot stop us” cc. Eager to see Kirko deliver and pipeline progression. Expecting those small FDA approvals soon too…
lol - 40 days after June is mid Aug. you are correct, I misspoke and responded too quickly. I actually have a job.
Are you still getting paid per post?
That’s the big question. I think we see launch volume for Prasco and further market penetration being big drivers. The reason I think this is the case is because they did a PR on the launch itself, which could be interpreted as a kickoff to a meaningful relationship and meaningful revenue impact to Q3. Either way it will be timing.
Meant Jul dude. Chillax. If I pointed out every mistype on your end you’d be crying in the corner.
Good comments. Note that the one-one time adjustment last Q had no bearing on revenues. Now we layer in Prasco launch quantity for Q3 and hopefully forward guidance for what a full Q with Prasco will look like as we’ll need to wait until end of June to find out.
Starting this year due to market cap increasing we will become an accelerated filer so they will report Q & Ks little earlier starting with Q1 reporting in July.
Not much volume though. Might be able to pick up couple hundred bucks here and there, but is inconsistent. Looking forward to this week’s call! The call that will set the tone and trajectory for the year.
It included brand + authorized generics. Generic entrance should more than cut the number in half, but generics seem to be struggling to get API. What we should see is a slower total market decrease driven by delay in mix shift towards generics. Could buy Elite some time for situation to clear up before they enter market.